Researchers at Seqirus Holly Springs)


Leaders in influenza

Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia.

We utilise both egg and cell-based technologies for influenza vaccine production and have developed the only adjuvanted seasonal influenza vaccine for elderly populations. Our scientists continue to optimise these innovative technologies whilst working on longer-term transformational approaches to influenza protection.

As part of the CSL Group, we have been producing influenza vaccine in Melbourne, Australia since the 1940’s. Our site in Liverpool UK, is a Centre of Excellence for adjuvanted influenza vaccine manufacturing while our state-of-the-art production facility in Holly Springs US, was purpose-built to harness newer cell-based technology.

Little boy with bandaid

About Influenza

Influenza is a common, highly contagious infectious disease that can cause severe illness and life-threatening complications in many people.

Learn more
  • 3 to 5 million

    Cases of severe illness resulting from annual flu epidemics.*

  • up to 650,000

    potential respiratory deaths linked to seasonal flu each year.*

  • US$27 billion

    Annual medical care and lost labour costs in the US alone.^

Areas of expertise


We are one of the world’s largest influenza vaccine companies with a singular global focus on influenza.

Pandemic Response Solutions

Experts agree that there will be another influenza pandemic this century1. Seqirus offers a portfolio of pandemic vaccines and services for rapid response.

Consumer Pain Campaign AU 1

Seqirus is the largest fully integrated commercialisation partner for vaccines and pharmaceuticals in Australia and New Zealand.

AVAT / Q Vax - red bellied black snake
Antivenoms & Q fever Vaccine

Seqirus is the supplier of a unique range of antivenoms and Q fever vaccine for the Australian government.

*World Health Organisation. Influenza (seasonal) Fact Sheet, November 2018. Available online: (Accessed March 2019)
^de Boer, P. et al, A systematic review of health economic consequences of quadrivalent influenza vaccination, Expert review of Pharmacoeconomics & Outcomes Research, Volume 17, 2017 - Issue 3, p249-265.
World Health Organisation. Newsroom Feature. 8 Things to know about pandemic influenza. Available online: (Accessed June 2019)


UK/FLU/0519/0080 August 2019


Seqirus, as part of the CSL Group, is bound by CSL’s Code of Responsible Business Practice (the Code).

Learn more
Our Company

Seqirus is one of the largest influenza vaccine manufacturers in the world.

Learn more

We know that partnerships can accelerate innovation and delivery of pioneering solutions that safeguard people and our communities.

Learn more